Ocugen, Inc. Common Stock
Symbol: OCGN (NASDAQ)
0.00
▼ (-100.00%) -1.040
Company Description:
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Key Stats
- Today's Open: $0
- Today's High: $0
- Today's Low: $0
- Today's Volume: 0
- Yesterday Close: $1.04
- Yesterday High: $1.06
- Yesterday Low: $1.03
- Yesterday Volume: 1.67M
- Last Min Volume: 0
- Last Min High: $0
- Last Min Low: $0
- Last Min VWAP: $0
Company Profile
- Name: Ocugen, Inc. Common Stock
- Website: https://www.ocugen.com
- Listed Date: 2014-12-03
- Location: MALVERN, PA
- Market Status: Active
- CIK Number: 0001372299
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $321.67M
- Round Lot: 100
- Outstanding Shares: 312.30M
- Asset Type: CS
RECENT FILINGS FOR OCGN
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-05 | 8-K | View |
| 2025-08-11 | 8-K | View |
| 2025-08-11 | 424B5 | View |
| 2025-08-04 | 10-Q | View |
| 2025-08-01 | 8-K | View |
| 2025-07-30 | 8-K | View |
| 2025-07-29 | 8-K | View |
| 2025-07-17 | SCHEDULE 13G/A | View |
| 2025-07-09 | 144 | View |
| 2025-07-01 | 8-K | View |
| 2025-06-23 | 8-K | View |
| 2025-06-17 | 8-K | View |
| 2025-06-12 | 3/A | View |
| 2025-06-11 | 144 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 4 | View |
| 2025-06-09 | 3 | View |
Latest News on OCGN